Cardiovascular Systems’ (CSII) “Buy” Rating Reiterated at Aegis

Aegis reissued their buy rating on shares of Cardiovascular Systems (NASDAQ:CSII) in a research report released on Monday morning, Zacks.com reports.

A number of other research firms also recently commented on CSII. Northland Securities increased their target price on shares of Cardiovascular Systems from $40.00 to $45.00 and gave the company an outperform rating in a research report on Wednesday, December 16th. TheStreet raised shares of Cardiovascular Systems from a d+ rating to a c rating in a research report on Wednesday, February 3rd. SVB Leerink increased their target price on shares of Cardiovascular Systems from $45.00 to $50.00 and gave the company an outperform rating in a research report on Monday, December 14th. Finally, Needham & Company LLC increased their target price on shares of Cardiovascular Systems from $47.00 to $50.00 and gave the company a buy rating in a research report on Thursday, February 4th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Cardiovascular Systems currently has a consensus rating of Buy and an average price target of $46.75.

Shares of NASDAQ:CSII opened at $42.26 on Monday. Cardiovascular Systems has a 52 week low of $26.00 and a 52 week high of $48.28. The company’s 50 day moving average is $44.51 and its two-hundred day moving average is $38.00. The company has a current ratio of 6.25, a quick ratio of 5.61 and a debt-to-equity ratio of 0.08. The company has a market cap of $1.70 billion, a PE ratio of -64.03 and a beta of 1.19.

Several hedge funds have recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board acquired a new stake in shares of Cardiovascular Systems in the 4th quarter worth $1,339,000. Walleye Capital LLC acquired a new stake in shares of Cardiovascular Systems in the fourth quarter valued at about $3,086,000. Morgan Stanley increased its holdings in Cardiovascular Systems by 96.9% during the 4th quarter. Morgan Stanley now owns 203,284 shares of the medical device company’s stock valued at $8,896,000 after acquiring an additional 100,021 shares in the last quarter. Gyon Technologies Capital Management LP purchased a new position in Cardiovascular Systems during the 4th quarter valued at about $1,067,000. Finally, Janus Henderson Group PLC increased its holdings in Cardiovascular Systems by 0.9% during the 4th quarter. Janus Henderson Group PLC now owns 1,369,311 shares of the medical device company’s stock valued at $59,921,000 after acquiring an additional 11,610 shares in the last quarter. Institutional investors own 89.70% of the company’s stock.

Cardiovascular Systems Company Profile

Cardiovascular Systems, Inc, a medical device company, develops and commercializes various devices to treat peripheral and coronary artery diseases in the United States. The company offers peripheral artery disease products, which are catheter-based platforms to treat a range of plaque types in above and below the knee leg arteries, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products.

Recommended Story: Market Timing

Analyst Recommendations for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.